Hepatitis C infection and its management

Haemophilia

Volumn 6, Issue SUPPL. 1, 2000, Pages 133-137

  Lee, C A ^a,b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b WORLD FEDERATION OF HEMOPHILIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIVIRUS AGENT; BLOOD CLOTTING FACTOR CONCENTRATE; INTERFERON; RIBAVIRIN;

ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; DISEASE COURSE; GENOTYPE; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CANCER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; SAFETY; SCREENING; SEXUAL TRANSMISSION; SHORT SURVEY; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; BLOOD COMPONENT THERAPY; DISEASE MANAGEMENT; DISEASE TRANSMISSION; HEMOPHILIA A; LIVER DISEASE; REVIEW; VIROLOGY;

BLOOD COMPONENT TRANSFUSION; DISEASE MANAGEMENT; DISEASE TRANSMISSION; HEMOPHILIA A; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER DISEASES;

EID: 0033925999     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2000.00058.x     Document Type: Short Survey

References (22)

1. EASL. International Consensus Conference on Hepatitis C. Paris 26-28 February 1999 Consensus Statement. J Hepatol 1999; 30: 956-61 Reproduced in Haemophilia 1999, 5: 365-370.
2. EASL. International Consensus Conference on Hepatitis C. Paris 26-28 February 1999 Consensus Statement. J Hepatol 1999; 30: 956-61 Reproduced in Haemophilia 1999, 5: 365-370.
3. Kernoff PB, Lee CA, Karayiannis P, Thomas HC. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 1985, 60: 469-479.
4. Mannucci PM. The choice of plasma-derived clotting factor concentrates. Baillieres Clin Haematol 1996; 9: 273-90.
5. Evatt B. Cryoprecipitate: an unsafe choice of therapy for haemophilia. Haemophilia 1999; 5: 295-300.
6. Srivastava A. Factor replacement for haemophilia - should cryoprecipitate be used? Haemophilia 1999; 5: 301-5.
7. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994; 87: 555-61.
8. Griffioen A, Sabin CA, Devereux H, Yee TT, Lee CA. Natural history of hepatitis C virus in a cohort of individuals with clotting factor disorders treated with unsterilised clotting concentrates. Thromb Haemost. (Suppl.): abstract 1502, 1999.
9. Eyster ME, Fried MW, Di Besceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood 1994; 84: 1020-3.
10. Telfer PT, Devereux H, Savage K et al. Chronic hepatitis C virus infection in haemophilic patients: clinical significance of viral genotype. Thromb Haemost 1995; 74: 1259-64.
11. Eyster ME, Sherman KE, Goedert JJ, Katsoulidou A, Hatzakis A. for the Multicenter Hemophilia Cohort Study. Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. J Infect Dis 1999; 179: 1062-9.
12. Telfer P. Sexual transmission of hepatitis C virus. Haemophilia 1995; 1(Suppl. 4): 15-8.
13. Lee C. Hepatitis, hemophilia. Chapter. In: Zuckerman AJ, Thomas HC. eds. Viral Hepatitis 2nd edn. London: Churchill Livingstone. pp 515-26, 1998.
14. Colombo M, Mannucci PM, Brettler DB et al. Hepatocellular carcinoma in hemophilia. Am J Hematol 1991; 37: 243-6.
15. Darby SC, Ewart DW, Giangrande PLF et al. for the UK Haemophilia Centre Directors' Organisation. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997; 350: 1425-31.
16. Lee CA. Investigation of chronic hepatitis C infection in individuals with haemophilia. Br J Haematol 1997; 96: 425-6.
17. Baglin T, Beacham E. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor? Thromb Haemost 1998; 80: 1036-7.
18. Bhagani S, Sabin C, Dean J, Miller R, Mistry P, Lee CA. Interferon-alpha-2B/Ribavirin combination therapy for chronic genotype 1 HCV in haemophilic patients - early results. Haemophilia 1998; 4: 262.
19. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
20. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
21. Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42: 744-9.
22. Baudo F, Caimi TM, Redaelli R et al. Orthotopic liver transplantation in a patient with severe haemophilia A and with advanced liver cirrhosis. Haemophilia 1999; 5: 276-7.